AIDS TREATMENT NEWS Issue #391, May 30, 2003
John S. James

Atazanavir (brand name Reyataz(TM)) is a new protease inhibitor developed by Bristol-Myers Squibb that is likely to be approved soon. A May 13, 2003 hearing of the FDA's Antiviral Drugs Advisory Committee decided that the drug has been proven safe and effective, and recommended approval.

Atazanavir, taken once per day, caused much less cholesterol and triglyceride problems than the other protease inhibitors with which it has been compared; however, this improvement did not seem to translate to less lipodystrophy, in the limited data now available. Atazanavir may need to be "boosted" with a small dose of ritonavir in order to be most effective with experienced patients. And some drug interactions will need to be watched carefully to prevent excessive blood levels of atazanavir, which could cause potentially serious changes in heart rhythm.

For much more extensive information on atazanavir see the two documents prepared for the May 13 hearing -- one by the FDA staff, the other by Bristol-Myers Squibb. They are at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950b1.htm

Remember that this information was current as of May 2003, and will become obsolete as new data become available.

030530
ATN39103

Copyright © 2003 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .